Roche teaches Schiffbruch mit einstigem Hoffnungsträger – Einschätzung zur Lungenkrebsstudie

On By Pranco

AbEinschätzung zur Lungenkrebsstudie

Roche has led Schiffbruch with a certain Hoffnungsträger

Der Wirkstoff Tiragolumab failed to achieve significant results in a Leben Phase III study of lung cancer patients. A solution has been found for Roche who has undergone the treatment of American medicine.

Rupen Boyadjian
Roche teaches Schiffbruch mit einstigem Hoffnungsträger – Einschätzung zur Lungenkrebsstudie

This is not the first time that Roche has undergone a Schlappe treatment with the immunotherapeutic treatment.

Image: Zvg/Roche

One of Roche’s major programs has had a long hiatus. Antibody therapy cannot prolong the life of patients with small lung disease when combined with Roche’s Immunotherapy Tecentriq. The result is that you can avoid the kickback.